ArticleGeroScience2026
The association between uric acid and incident cardiovascular events amongst healthy, community-dwelling older adults.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is inconsistency in historical evidence on the relationship between uric acid (UA) level and cardiovascular disease (CVD) risk. This study aimed to investigate the association between UA and risk of incident CVD in healthy older adults who were free of CVD initially.
methods10,794 participants aged ≥ 70 years from the ASPREE trial were included. Primary outcomes were incident CVD and incident major adverse cardiovascular events (MACE). Secondary outcomes included myocardial infarction (MI), stroke, and hospitalisation for heart failure (HHF). Multivariable Cox-proportional-hazard models analysed the association between baseline UA levels and study outcomes. Restricted cubic splines identified any non-linear associations, a subgroup analysis explored potential effect modifiers.
resultsOver a median of 8.4 years, 1078 CVD and 826 MACE events occurred. In full-adjusted model, higher UA was significantly associated with an increased risk of incident CVD [HR 1.26 (95% CI: 1.03-1.56), p = 0.04] and MACE [1.32, 1.04-1.69, p = 0.05], and MI [1.50, 1.04-2.16, p = 0.08]. Restricted cubic splines showed a monotonic association between UA and incident CVD, MACE and MI. UA was not significantly associated with stroke and HHF. Subgroup analyses showed no significance between UA and sex, obesity, diabetes, or high blood pressure for major CVD outcomes (all p for interaction > 0.05).
conclusionsHigher UA levels were associated with significantly increased risk of incident CVD, MACE, MI events in healthy older adults. This highlighted UA as a potential modifiable risk factor, warranting future studies on UA-lowering medication in CVD primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.